Ken Blount, PhD, CSO Rebiotix Inc., A Ferring Company Summary Every person carries an extensive and diverse community of microbes that influence daily health The community of healthy human bacterial microbiota can be disrupted by antibiotics, leading to C. diff infections and recurrent C. diff infections Investigational live biotherapeutics aim to reduce recurrent C. diff infections In […]
Microbiota Restoration Therapy Presentations
Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
Lindy Bancke PharmD1, Xin Su MD11Rebiotix, Inc., a Ferring Company, Roseville, MN, USA Background Microbiota-based treatments have shown promise to reduce recurrence, morbidity, and mortality for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable clinical efficacy data are needed to support regulatory approvals that broaden patient access. Here we provide cumulative data from 5 […]
Antimicrobial Resistance Genes were Reduced Following Administration of Investigational Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
Heidi Hau, PhD1, Dana Walsh PhD1, Carlos Gonzalez MS2, Bill Shannon PhD MBA2, Ken Blount11Rebiotix Inc, a Ferring company, Roseville, MN, USA; 2BioRankings, St. Louis, MO, USA Background Microbiota-based treatments are increasingly evaluated as a strategy to reduce recurrence of Clostridioides difficile infection (rCDI), and their proposed mechanisms Intestinal colonization by antimicrobial resistant (AMR) pathogens […]
Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trials
Sahil Khanna, MBBS, MS; Gail Hecht, MD; Erik Dubberke,MD, MSPH; Robert Orenstein, DO; Christine Lee, MD; Dale Gerding, MD Summary One dose of RBX2660 administered via enema is more effective than placebo for recurrent CDI Responders to RBX2660 Distinct microbiome changes from baseline in contrast to those who fail active treatment Responders to RBX2660 Different microbiota composition […]
Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis
Courtney Jones, BS, Rebiotix Inc., Roseville, MN USA Summary Rebiotix has developed a standardized, quality controlled microbiota therapy to treat recurrent Clostridium difficile infection (CDI). This product, RBX2660, is a broad spectrum community of microbes derived from raw material provided by healthy donors. RBX2660 has been repeatedly studied against well-known analytical methods to show preservation of bacteria throughout the manufacturing […]